Sign in
CompletedPhase 3

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Key facts

Who runs it
89bio, Inc.
Where
Amarillo, Atlanta, Austin, Bridgeport, Burke, Chandler, Charleston, Chattanooga, Chicago, Cincinnati, Clarksville, Clearwater, Columbus, Conway, Dallas, East Syracuse, Eugene, Flint, Graham, Hialeah Gardens, Homestead, Houston, Huntington Park, Jonesboro, Kansas City, Lampasas, Las Vegas, Lawrenceville, Little Rock, Long Beach, Los Angeles, Mansfield, Marrero, Miami Lakes, Middleburg Heights, Miramar, Morganton, New Windsor, New York, North Massapequa, Northridge, Oklahoma City, Orlando, Oxon Hill, Panama City, Panorama City, Peoria, Port Orange, Richmond, Richmond Hill, Salt Lake City, San Antonio, Santa Ana, Shreveport, Sparta, St Louis, Stow, Syracuse, Tampa, Thousand Oaks, Tucson, Tullahoma, Tustin, West Des Moines, Wheat Ridge, Wichita, and Wichita Falls, United StatesSee the 71 sitesAlso in 19 other countries, 90 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
369 people enrolled
Started
15 Jun 2023
Ended
9 Apr 2026
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Pegozafermin
  • Placebo
Record updated
7 July 2026

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age ≥22 years
  • Willing to enter a medication/lifestyle stabilization period during the screening period, which means maintaining those stable medication, eating, and exercise habits for the duration of the study
  • Subjects should be on stable background Lipid Modifying Therapy (LMT) to manage ASCVD for a minimum of 4 weeks prior to first qualifying TG

Who cannot take part

  • A history of symptomatic gallstone disease, gallstone pancreatitis (unless treated with cholecystectomy), or any other ongoing symptomatic biliary disease
  • Acute pancreatitis within 6 months prior to Screening
  • Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
  • Type 1 diabetes mellitus
  • Known or suspected familial chylomicronemia syndrome (FCS) (Type 1 hyperlipoproteinemia); Other inclusion and exclusion criteria may apply
  • Uncontrolled or newly diagnosed (≤3 months since diagnosis) Type 2 diabetes mellitus as determined by the Principal Investigator. Subjects must have HbA1c level ≤9.5% at Screening. Medications for glucose management must be stable for at least 4 weeks prior to Screening
  • Subjects with chronic pancreatitis

Where in United States

Also in 19 other countries, 90 sites

  • Amarillo, TexasHospital not named in the registry
  • Atlanta, GeorgiaHospital not named in the registry
  • Austin, TexasHospital not named in the registry
  • Bridgeport, ConnecticutHospital not named in the registry
  • Burke, VirginiaHospital not named in the registry
  • Chandler, ArizonaHospital not named in the registry
  • Charleston, South CarolinaHospital not named in the registry
  • Chattanooga, TennesseeHospital not named in the registry
  • Chicago, IllinoisHospital not named in the registry
  • Cincinnati, OhioHospital not named in the registry
  • Clarksville, TennesseeHospital not named in the registry
  • Clearwater, FloridaHospital not named in the registry
  • Columbus, OhioHospital not named in the registry
  • Columbus, OhioHospital not named in the registry
  • Conway, ArkansasHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • East Syracuse, New YorkHospital not named in the registry
  • Eugene, OregonHospital not named in the registry
  • Flint, MichiganHospital not named in the registry
  • Graham, TexasHospital not named in the registry
  • Hialeah Gardens, FloridaHospital not named in the registry
  • Homestead, FloridaHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Huntington Park, CaliforniaHospital not named in the registry
  • Jonesboro, ArkansasHospital not named in the registry
  • Kansas City, MissouriHospital not named in the registry
  • Lampasas, TexasHospital not named in the registry
  • Las Vegas, NevadaHospital not named in the registry
  • Lawrenceville, GeorgiaHospital not named in the registry
  • Little Rock, ArkansasHospital not named in the registry
  • Long Beach, CaliforniaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Mansfield, TexasHospital not named in the registry
  • Marrero, LouisianaHospital not named in the registry
  • Miami Lakes, FloridaHospital not named in the registry
  • Middleburg Heights, OhioHospital not named in the registry
  • Miramar, FloridaHospital not named in the registry
  • Morganton, North CarolinaHospital not named in the registry
  • New Windsor, New YorkHospital not named in the registry
  • New YorkHospital not named in the registry
  • North Massapequa, New YorkHospital not named in the registry
  • Northridge, CaliforniaHospital not named in the registry
  • Oklahoma City, OklahomaHospital not named in the registry
  • Orlando, FloridaHospital not named in the registry
  • Oxon Hill, MarylandHospital not named in the registry
  • Panama City, FloridaHospital not named in the registry
  • Panorama City, CaliforniaHospital not named in the registry
  • Peoria, ArizonaHospital not named in the registry
  • Port Orange, FloridaHospital not named in the registry
  • Richmond, VirginiaHospital not named in the registry
  • Richmond Hill, New YorkHospital not named in the registry
  • Salt Lake City, UtahHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • Santa Ana, CaliforniaHospital not named in the registry
  • Santa Ana, CaliforniaHospital not named in the registry
  • Shreveport, LouisianaHospital not named in the registry
  • Sparta, New JerseyHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • Stow, OhioHospital not named in the registry
  • Syracuse, New YorkHospital not named in the registry
  • Tampa, FloridaHospital not named in the registry
  • Thousand Oaks, CaliforniaHospital not named in the registry
  • Tucson, ArizonaHospital not named in the registry
  • Tullahoma, TennesseeHospital not named in the registry
  • Tustin, CaliforniaHospital not named in the registry
  • West Des Moines, IowaHospital not named in the registry
  • Wheat Ridge, ColoradoHospital not named in the registry
  • Wheat Ridge, ColoradoHospital not named in the registry
  • Wichita, KansasHospital not named in the registry
  • Wichita Falls, TexasHospital not named in the registry

About the trial

What the trial wants to find out

To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.

The 3 groups in the trial

  • Pegozafermin - 30mg once a weekTreatment being tested

    Treatment: Pegozafermin

  • Pegozafermin - 20mg once a weekTreatment being tested

    Treatment: Pegozafermin

  • Placebo once a weekPlacebo, for comparison

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia (SHTG): The ENTRUST Study
Record updated
7 July 2026